A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study
William C. Miller(Hennepin Healthcare Research Institute), David Burns(Norwegian Womens Public Health Association), Sarah A. Reifeis(University of North Carolina at Chapel Hill), Tetiana Kiriazova(Ukrainian Institute of Public Health Policy), Kostyantyn Dumchev(Ukrainian Institute of Public Health Policy), Estelle Piwowar‐Manning(Johns Hopkins University), Kathryn E. Lancaster(Wake Forest University), Viet Anh Chu, Samsuridjal Djauzi(University of Indonesia), Trần Việt Hà(University of North Carolina at Chapel Hill), Vivian F. Go(University of North Carolina at Chapel Hill), Jeremy Sugarman(Johns Hopkins Berman Institute of Bioethics), Paul Richardson(University of Liverpool), Hepa Susami(University of Indonesia), Erica L. Hamilton(Family Health International 360), Michael G. Hudgens(University of North Carolina at Chapel Hill), Susan H. Eshleman(Johns Hopkins University), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Steffanie A. Strathdee(University of California San Diego), Zubairi Djoerban(University of Indonesia), Irving Hoffman(Communities In Schools of Orange County), David S. Metzger(California University of Pennsylvania), Duong D Bui(Ministry of Health), Scott M. Rose(Family Health International 360), Carl A. Latkin(Johns Hopkins University), Сергій Дворяк(Academy of Labour Social Relations and Tourism), Katie R. Mollan(University of North Carolina at Chapel Hill)
Cited by 97
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
The Natural History of Hepatitis C Virus Infection
|JAMA|2000|1.1k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891